about
Oxidative DNA double strand breaks and autophagy in the antitumor effect of sterically hindered platinum(II) complexes in NSCLCsOleanolic acid-NO donor-platinum(II) trihybrid molecules: Targeting cytotoxicity on hepatoma cells with combined action mode and good safety.Study on Antitumor Platinum(II) Complexes of Chiral Diamines with Dicyclic Species as Steric Hindrance.Cytotoxicity profile of novel sterically hindered platinum(II) complexes with (1R,2R)-N(1),N(2)-dibutyl-1,2-diaminocyclohexane.Antitumor platinum(II) complexes of N-cyclobutyl-1R,2R-diaminocyclohexane with dicarboxylates as leaving groups.Potent anticancer activity and possible low toxicity of platinum(II) complexes with functionalized 1,1-cyclobutanedicarboxylate as a leaving ligand.Antitumor platinum(II) complexes of N-monoalkyl 1R,2R-diamino-cyclohexanes with 3-(nitrooxy)cyclobutane-1,1-dicarboxylate as a leaving group.Nitric oxide donor-based platinum complexes as potential anticancer agents.Antitumor platinum(II) complexes containing platinum-based moieties of present platinum drugs and furoxan groups as nitric oxide donors: synthesis, DNA interaction, and cytotoxicity.Design, synthesis and in vitro cytotoxicity of novel dinuclear platinum(II) complexes.Platinum(II) complexes with N-monoalkyl 1R,2R-diaminocyclohexane derivatives as carrier ligands and 3-hydroxycyclobutane-1,1-dicarboxylate as a leaving group: potent cytotoxicity and DNA binding ability.Bifunctional Platinum(II) Complexes with Bisphosphonates Substituted Diamine Derivatives: Synthesis and In vitro Cytotoxicity.Biotinylated platinum(IV) complexes designed to target cancer cells.Exploring the Hydrolytic Behavior of the Platinum(IV) Complexes with Axial Acetato Ligands.Improve the anticancer potency of the platinum(II) complexes through functionalized leaving group.Novel hypoxia-targeting Pt(iv) prodrugs.A study on platinum(iv) species containing an estrogen receptor modulator to reverse tamoxifen resistance of breast cancer.DN604: A platinum(II) drug candidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells.Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action.Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen ReceptorHypoxia-Targeting Organometallic Ru(II)-Arene Complexes with Enhanced Anticancer Activity in Hypoxic Cancer CellsInsight into the antitumor actions of sterically hindered platinum(ii) complexes by a combination of STD NMR and LCMS techniquesConstruction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin ResistanceDinuclear Organoruthenium Complexes Exhibiting Antiproliferative Activity through DNA Damage and a Reactive-Oxygen-Species-Mediated Endoplasmic Reticulum Stress PathwayLight-activated ruthenium (II)-bicalutamide prodrugs for prostate cancerA naphthalimide derivative can release COS and form H2S in a light-controlled manner and protect cells against ROS with real-time monitoring ability
P50
Q33761590-FD1024AE-ED80-43DF-BD6D-53551C97819BQ38753053-24C40653-7907-4645-859D-71F83F723AE9Q38845958-267B1BCC-2B65-451F-AEDA-105F9509C21AQ38887169-CF1FAC15-F189-49E5-A057-4E8B5FE79084Q38929524-B2FEF020-6AAE-4900-BEFB-010378B3D163Q38953342-C2D64383-E968-4017-B1A8-520155BCE679Q38967610-BDACCB8F-464A-4947-9B1F-D0226C1173C4Q39270724-9A259D7E-63CC-4368-BB0B-79E4A3DFF413Q39283608-8C33C5B0-8F63-4675-BD06-42735240BEF7Q39593482-230D44CE-E33C-47EA-8A91-D250D4057236Q46148102-631D9C3F-2B0F-455F-BA27-A6151E861923Q47603642-664C7AC4-EBEC-4CC4-8A03-64D18660F22BQ47667908-5477D33C-F035-490D-AE31-38AA51A2A4FFQ47849260-B4B5C369-044A-4C49-A5E5-FAB72785CFE5Q47945912-532B218E-7CDF-4362-87AE-7CCADC735055Q48113171-6C6713F6-5040-4A38-974C-46FED268F559Q48213257-CCA43387-BCFF-407D-96C2-0BCD3A2F525CQ49353835-63CC3D58-80C2-4B8B-8EC0-1346D7DFA793Q54977915-C3B14F16-FDBB-46D0-BC52-8195EF903DC4Q88395559-9148DF94-8287-4670-A54E-47AA8647D5E5Q89311545-DADB3DBE-BD54-47FC-9197-FE2F62589DC7Q89540664-804D7EE3-4C92-416A-A01B-27B49446BD88Q91108077-BBBD038C-AC82-4DA6-AC7B-8CDF0C325FC4Q91191135-6CE2DB01-D1AE-4DDC-AF34-7795DEAB2C39Q91757098-FE98B4F9-0B57-42B9-B80B-1945D9B101CEQ91981974-5420D79F-39F3-4314-9063-F28E6A67F174
P50
description
researcher (ORCID 0000-0002-9365-7727)
@en
name
Jian Zhao
@en
type
label
Jian Zhao
@en
prefLabel
Jian Zhao
@en
P31
P496
0000-0002-9365-7727